WASP Update- OTC BB - 1.43 - HOUSTON--(BUSINESS WIRE)--Sept. 8, 1999--
STRONG BUY/AGGRESSIVE GROWTH/WASATCH PHARMACEUTICAL (OTC BB:WASP)
Investors' Alert's most recent recommendations, E-Net Financial Corp. (OTC BB:ENNT), Corfacts Inc. (OTC BB:CFCC) and Vector Energy Corp. (OTC BB:VECT), performed very well short term. ENNT went up almost 85% in only a week, CFCC went up almost 80% in a week and VECT went up over 380% in less than 2 weeks.
Investors' Alert's next pick is Wasatch Pharmaceutical (OTC BB:WASP). Thomas Loyd, chief editor of Investors' Alert stated, "This stock should trade up to $3.50 short term and $6.00 within 6 months."
Thomas Loyd went on to state, "WASP's wholly-owned subsidiary American Institute of Skin Care we believe will show significant revenue growth this year and next from its skin care products, which in a clinical setting have an unbelievable 90% success rate for seven major skin disorders. These products will be worth hundreds of millions, if not billions, on the over-the-counter markets."
WASP is a fourteen-year-old company with a track record of outstanding achievements in the field of dermatology. Over this period of time, WASP management has focused exclusively on their new product research & development. Their efforts are now bearing tremendous fruit in the form of more than seven over-the-counter products protected under trade secret status (with patents applied for).
In WASP's Executive Summary released in August 1999 it stated that: "The products and medical therapies developed by this company represent the most important breakthrough in the field of dermatology in the last fifty years." Company activities have been centered on research in the area of serious skin diseases along with dramatic successes in the area of skin rejuvenation.
Thomas Loyd stated that he believes the Company's prolific successes in the area of skin diseases include the development of medications (in FDA-approved laboratories) for cystic acne, eczema, seborrhea, contact dermatitis, mollus###, folliculitis, acne rosacea and less prevalent skin diseases. These skin disorders account for more than 70% of all the business in the field of dermatology and over $7 billion in annual expenditures for which there are no safe, effective therapies, except, we believe, those developed by Wasatch.
Thomas Loyd concluded, "Because these therapies developed by WASP dominate this discipline of medicine, the company has elected to market their products via company-owned clinics throughout the United States. This decision resulted in the establishment of two initial research clinics in the state of Utah where research and 90% success rates duplicated from independent clinical trials have continued in conjunction with Chesebrough Pond of Greenwich, Conn. These clinics are now online with insurance providers independent of HMOs.
"WASP's goal is to open up one new clinic per month over the next two years. They are in final negotiations with the Vector Group, an investment banking group based in California that will place restricted stock with their institutional clients to fund this $10 million expansion program. This funding is critical to the company becoming a leader in the dermatology field through the marketing and sales of their proprietary products.
"We believe FDA approvals for WASP's seven dermatological products should come within the next year, and there will be no more clinical trials needed. Upon approval, we have heard Loreal wants to negotiate for two of the products, and Carter Wallace (NYSE:CAR) wants all of them."
Symbol- WASP
Shares Outstanding 18,000,000
Float (est.) 5,000,000
52 Week High/Low- .11 - 2.50
6 mo. Target- $6.00
Investors' Alert is an independent research firm with paid subscribers. Subscriptions are $139.00/year for Investors' Alert newsletter service. This report is based on Investors' Alert independent analysis but relies on information supplied by sources believed to be reliable. The information contained in this report is not intended to be, and shall not constitute, an offer to sell nor solicitation of any offer to buy any security. Thomas Loyd has purchased 9,000 shares of WASP in the past 9 days and may purchase more without notice, but is not affiliated with WASP. Thomas Loyd may sell his shares at any time without notice. Copyright (c) 1999 Loyd Financial Consulting. All rights reserved.
CONTACT: Investors' Alert, Houston
Thomas Loyd, 800/398-5725
Fax: 713/973-5783 |
